The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer

European Radiology

Volumn 19, Issue 6, 2009, Pages 1347-1357

  Kumar, Amandeep ^a   Kumar, Rakesh ^a   Seenu, Vathalaru ^a   Gupta, Sidharatha Datta ^a   Chawla, Madhavi ^a   Malhotra, Arun ^a   Mehta, Sada Nand ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

FDG PET CT; Locally advanced breast cancer; Neoadjuvant chemotherapy; Treatment response evaluation

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVANCED CANCER; ARTICLE; ASPIRATION BIOPSY; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; COMPUTER ASSISTED TOMOGRAPHY; IMAGE SUBTRACTION; METHODOLOGY; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REPRODUCIBILITY; TREATMENT OUTCOME;

ADULT; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 67349209897     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-009-1303-z     Document Type: Article

References (29)

1. Jemal A, Clegg LX, Ward E et al (2004) Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 101:3-27
2. Ferlay J, Autier P, Boniol M et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18(3):581-592
3. Haagensen CD, Stout AP (1942) Carcinoma of the breast: I. Results of treatment. Ann Surg 116:801-815
4. Haagensen CD, Stout AP (1943) Carcinoma of the Breast: II. Criteria of operability. Ann Surg 118:859-870 1032-51
5. Bonadonna G, Valagussa P, Zucali R et al (1995) Primary chemotherapy in surgically resectable breast cancer. CA Cancer J Clin 45:227-243
6. Wang H, Lo S (1996) Future prospects of neoadjuvant chemotherapy in treatment of primary breast cancer. Semin Surg Oncol 12:59-66
7. Clavel M, Catimel G (1993) Breast cancer: Chemotherapy in the treatment of advanced disease. Eur J Cancer 29A:598-604
8. Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on loco-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493
9. Heys SD, Eremin JM, Sarkar TK et al (1994) Role of multimodality therapy in the management of locally advanced carcinoma of the breast. J Am Coll Surg 179:493-504
10. Frei E III, Canellos GP (1980) Dose, a critical factor in cancer chemotherapy. Am J Med 69:585-594
11. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
12. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
13. Price P, Jones T (1995) Can Positron Emission Tomography be used to assess subclinical response to cancer therapy? The EC PET Oncology Concerted action and the EORTC PET study. Eur J Cancer 31A:1924-1927
14. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R (1993) Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 11:2101-2111
15. Bassa P, Kim E, Inoue T et al (1996) Evaluation of preoperative chemotherapy using PET with Fluorine-18 fluorodeoxyglucose in breast cancer. J Nucl Med 37:931-938
16. Schelling M, Avril N, Nahrig J et al (2000) Positron emission tomography using [18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18:1689-1695
17. Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L (2006) Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18 F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 24:5366-5372
18. Sataloff DM, Mason BA, Prestipino AJ et al (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome. J Am Coll Surg 180:297-306
19. Smith IC, Welch AE, Hutcheon AW et al (2000) Positron emission tomography using (18 F)-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676-1688
20. Jansson T, Westlin JE, Ahlstrom H et al (1996) Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation? J Nucl Med 13:931-938
21. Mankoff DA, Dunnwald LK, Gralow JR et al (2003) Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 44:1806-1814
22. Bruce DM, Evans NT, Heys SD et al (1995) Positron emission tomography: 2-deoxy-2 [18F]-fluoro-D-glucose uptake in locally advanced breast cancers. Eur J Surg Oncol 21:280-283
23. Tiling R, Linke R, Untch M et al (2001) 18F-FDG PET and 99mTcsestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: A comparative study. Eur J Nucl Med 28:711-720
24. Kim SJ, Kim SK, Lee ES, Ro J, Kang SH (2004) Predictive value of [18F] FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann of Oncol 15:1352-1357
25. Pio BS, Park CK, Pietras R et al (2006) Usefulness of 3′-[F-18] fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 8:36-42
26. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO (2007) Imaging early changes in proliferation at 1 week post chemotherapy: A pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34(9):1339-1347
27. McDermott GM, Welch A, Staff RT et al (2007) Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 102(1):75-84
28. Li D, Yao Q, Li L, Wang L, Chen J (2007) Correlation between hybrid 18F-FDG PET/CT and apoptosis induced by neoadjuvant chemotherapy in breast cancer. Cancer Biol Ther 6:1442-1448
29. Meisamy S, Bolan PJ, Baker EH et al (2004) Neoadjuvant chemotherapy of locally advanced breast cancer: Predicting response with in vivo (1)H MR spectroscopy - a pilot study at 4 T. Radiology 233(2):424-431